- CEO
- Fang Cai Cheng
- Full Time Employees
- 438
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No.3 Beibuwan Middle Road Beihai GZ China 536000
- IPO Date
- Jan 14, 2003
- Business
- Beihai Gofar Chuanshan Biological Co., Ltd. (600538.SS) is a China-based company primarily engaged in the production, distribution, and sale of pharmaceutical products, pesticides, and related medical services. The company offers a range of proprietary Chinese medicines and medical devices, including Haibao pearl eye drops, pearl powder, nacre powder, Guofa brand Weichangning gastroenteric granules, honeysuckle mixture, fertilizer syrup, Haima brand herbal medicines, sea snake medicinal liquor, and ethanol disinfectants; it also provides molecular diagnostics, nucleic acid extraction systems such as silicon-magnetic integrated DNA quantitative extraction workstations and automatic microDNA extraction workstations, judicial IVD services, molecular medical imaging centers, tumor radiotherapy centers, and tumor telemedicine technical services. Operations span pharmaceutical manufacturing, pharmaceutical distribution, deoxyribonucleic acid identification and services, and other segments, with a focus on domestic markets in China and subsidiaries primarily in Guangxi and Hunan provinces. Founded in 1993 and headquartered at No. 3, Beibuwan Middle Road, Haicheng District, Beihai City, Guangxi Zhuang Autonomous Region, the company leverages marine resources from the Beibu Gulf for biopharmaceuticals, biopesticides, and seaweed liquid fertilizers. In June 2021, the company changed its Chinese name from Beihai Guofa Marine Biotechnology Co., Ltd. to Beihai Guofa Chuanshan Biological Co., Ltd., reflecting its emphasis on biological products; more recently, in 2025, Chairman Jiang Ye completed a shareholding increase of approximately 4.8 million shares valued at RMB 30 million through centralized bidding on the Shanghai Stock Exchange, signaling strengthened insider confidence amid ongoing operations in the pharmaceutical and biotech sectors.